Premium
P2‐062: Platelet ADAM10 levels in elderly with mild Alzheimer's disease
Author(s) -
Manzine Patricia,
Barham Elizabeth,
Assis Carvalho Vale Francisco,
Araújo Heloisa,
Cominetti Márcia,
Pavarini Sofia
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.766
Subject(s) - dementia , biomarker , blot , disease , medicine , platelet , alzheimer's disease , adam10 , psychology , oncology , gastroenterology , biochemistry , biology , gene , metalloproteinase , disintegrin , matrix metalloproteinase
Background: Previous research has identified various molecular biomarkers that have a direct or indirect relationship with the physiopathology of Alzheimer’s Disease (AD). One biomarker that is currently being studied involves a decrease in ADAM10 platelets among patients with AD. The aim of this study was to examine the effectiveness of using ADAM10 platelet levels to contribute to the early detection of AD. Methods: Two groups were formed, on the basis of the participants’ Clinical Dementia Ratings. The AD group included 10 elderly patients with mild AD (CDR1). The non-AD group included 8, participants with no signs of dementia (CDR0), matched with respect to age, sex and educational level to the AD group participants. This is a case-comparison study funded by a public research foundation in Brazil. The clinical assessment and diagnosis of the participants was based on the NINCDS-ADRDA criteria. Once this information was available, biological material was collected. Platelet proteins were resolved on SDS-PAGE (10%) and ADAM10 was identified by Western Blotting, using a monoclonal antibody to detect this protein. b-actin was used as the endogenous control. The blots were developed using the colorimetric kit Amplified Opti-4CN Substrate (BioRad) and measured with the Quantity One software. The means for the ADAM10/b-actin ratio in the AD and non-AD groups were compared using the Mann-Whitney test. Results: The mean ADAM10/b-actin ratio was significantly higher in the non-AD group (M 1⁄4 1.25, s.d. 1⁄4 0.14) than in the AD group (M 1⁄4 0.57, s.d. 1⁄4 0.15), (p < 0.0001). Conclusions: ADAM10 protein expression was lower in elderly patients with mild AD compared with a matched group of elderly people with no dementia, confirming previous studies. Thus, these results support the identification of ADAM10 as a platelet biomarker that can be used as an important auxiliary tool in the clinical diagnosis of AD. Further research to investigate the relationship between ADAM10 platelets and AD may permit additional contributions to the diagnosis of this disease.